2. Signaling Pathways
  3. PI3K/Akt/mTOR
  4. PI3K
  5. PI3KC2γ Isoform

PI3KC2γ

 

PI3KC2γ Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-15837
    SAR-260301
    		Inhibitor 99.95%
    SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC50 of 23 nM.
  • HY-112443
    AZD3458
    		Inhibitor 99.71%
    AZD3458 is a potent and remarkably selective PI3Kγ inhibitor with pIC50s of 9.1, 5.1, <4.5, and 6.5 for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively.
  • HY-19798
    PI4KIIIbeta-IN-9
    		Inhibitor 99.18%
    PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively.
  • HY-178371
    PI3KC2γ-IN-1
    		Inhibitor
    PI3KC2γ-IN-1 (Compound 23) is an orally active and selective PI3KC2γ inhibitor (IC50 = 4 nM). PI3KC2γ-IN-1 downregulats the Akt2-glycogen synthase (GS) signaling pathway, ultimately inhibiting the conversion of glucose to glycogen and reduces excessive glycogen accumulation in the liver. PI3KC2γ-IN-1 can significantly inhibit insulin-induced PI(3,4)P2 accumulation in both primary hepatocytes and HepG2 liver cancer cells. PI3KC2γ-IN-1 can be used for the study of glycogen storage diseases (GSDs).